Natalia Kunst1, Natasha K Stout1, Grace O'Brien2, Kurt D Christensen1,3, Pamela M McMahon1, Ann Chen Wu1,2, Lisa R Diller4,5, Jennifer M Yeh2,4. 1. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA. 2. Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA. 3. Broad Institute of MIT and Harvard, Boston, MA, USA. 4. Department of Pediatrics, Harvard Medical School, Boston, MA, USA. 5. Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract
BACKGROUND: Identification of children and infants with Li-Fraumeni syndrome prompts tumor surveillance and allows potential early cancer detection. We assessed the clinical benefits and cost-effectiveness of population-wide newborn screening for TP53 variants (TP53-NBS). METHODS: We simulated the impact of TP53-NBS using data regarding TP53-associated pediatric cancers and pathogenic or likely pathogenic (P/LP) TP53 variants from Surveillance, Epidemiology, and End Results; ClinVar and gnomAD; and clinical studies. We simulated an annual US birth cohort under usual care and TP53-NBS and estimated clinical benefits, life-years, and costs associated with usual care and TP53-NBS. RESULTS: Under usual care, of 4 million newborns, 608 (uncertainty interval [UI] = 581-636) individuals would develop TP53-associated cancers before age 20 years. Under TP53-NBS, 894 individuals would have P/LP TP53 variants detected. These individuals would undergo routine surveillance after detection of P/LP TP53 variants decreasing the number of cancer-related deaths by 7.2% (UI = 4.0%-12.1%) overall via early malignancy detection. Compared with usual care, TP53-NBS had an incremental cost-effectiveness ratio of $106 009 per life-year gained. Probabilistic analysis estimated a 40% probability that TP53-NBS would be cost-effective given a $100 000 per life-year gained willingness-to-pay threshold. Using this threshold, a value of information analysis found that additional research on the prevalence of TP53 variants among rhabdomyosarcoma cases would resolve most of the decision uncertainty, resulting in an expected benefit of 349 life-years gained (or $36.6 million). CONCLUSIONS: We found that TP53-NBS could be cost-effective; however, our findings suggest that further research is needed to reduce the uncertainty in the potential health outcomes and costs associated with TP53-NBS.
BACKGROUND: Identification of children and infants with Li-Fraumeni syndrome prompts tumor surveillance and allows potential early cancer detection. We assessed the clinical benefits and cost-effectiveness of population-wide newborn screening for TP53 variants (TP53-NBS). METHODS: We simulated the impact of TP53-NBS using data regarding TP53-associated pediatric cancers and pathogenic or likely pathogenic (P/LP) TP53 variants from Surveillance, Epidemiology, and End Results; ClinVar and gnomAD; and clinical studies. We simulated an annual US birth cohort under usual care and TP53-NBS and estimated clinical benefits, life-years, and costs associated with usual care and TP53-NBS. RESULTS: Under usual care, of 4 million newborns, 608 (uncertainty interval [UI] = 581-636) individuals would develop TP53-associated cancers before age 20 years. Under TP53-NBS, 894 individuals would have P/LP TP53 variants detected. These individuals would undergo routine surveillance after detection of P/LP TP53 variants decreasing the number of cancer-related deaths by 7.2% (UI = 4.0%-12.1%) overall via early malignancy detection. Compared with usual care, TP53-NBS had an incremental cost-effectiveness ratio of $106 009 per life-year gained. Probabilistic analysis estimated a 40% probability that TP53-NBS would be cost-effective given a $100 000 per life-year gained willingness-to-pay threshold. Using this threshold, a value of information analysis found that additional research on the prevalence of TP53 variants among rhabdomyosarcoma cases would resolve most of the decision uncertainty, resulting in an expected benefit of 349 life-years gained (or $36.6 million). CONCLUSIONS: We found that TP53-NBS could be cost-effective; however, our findings suggest that further research is needed to reduce the uncertainty in the potential health outcomes and costs associated with TP53-NBS.
Authors: Eric Jutkowitz; Fernando Alarid-Escudero; Hyon K Choi; Karen M Kuntz; Hawre Jalal Journal: Pharmacoeconomics Date: 2017-10 Impact factor: 4.981
Authors: Mark N Fluchel; Anne C Kirchhoff; Julia Bodson; Carol Sweeney; Sandra L Edwards; Qian Ding; Gregory J Stoddard; Anita Y Kinney Journal: Pediatr Blood Cancer Date: 2014-08-17 Impact factor: 3.167
Authors: Gislaine Custódio; Guilherme A Parise; Nilton Kiesel Filho; Heloisa Komechen; Cesar C Sabbaga; Roberto Rosati; Leila Grisa; Ivy Z S Parise; Mara A D Pianovski; Carmem M C M Fiori; Jorge A Ledesma; José Renato S Barbosa; Francisco R O Figueiredo; Elis R Sade; Humberto Ibañez; Sohaila B I Arram; Sérvio T Stinghen; Luciano R Mengarelli; Mirna M O Figueiredo; Danilo C Carvalho; Sylvio G A Avilla; Thiago D Woiski; Lisiane C Poncio; Geneci F R Lima; Roberto Pontarolo; Enzo Lalli; Yinmei Zhou; Gerard P Zambetti; Raul C Ribeiro; Bonald C Figueiredo Journal: J Clin Oncol Date: 2013-06-03 Impact factor: 44.544
Authors: Gillian D Sanders; Peter J Neumann; Anirban Basu; Dan W Brock; David Feeny; Murray Krahn; Karen M Kuntz; David O Meltzer; Douglas K Owens; Lisa A Prosser; Joshua A Salomon; Mark J Sculpher; Thomas A Trikalinos; Louise B Russell; Joanna E Siegel; Theodore G Ganiats Journal: JAMA Date: 2016-09-13 Impact factor: 56.272
Authors: Peter S Hall; Alison Smith; Claire Hulme; Armando Vargas-Palacios; Andreas Makris; Luke Hughes-Davies; Janet A Dunn; John M S Bartlett; David A Cameron; Andrea Marshall; Amy Campbell; Iain R Macpherson; Adele Francis; Helena Earl; Adrienne Morgan; Robert C Stein; Christopher McCabe Journal: Value Health Date: 2017-07-11 Impact factor: 5.725